Aadi Bioscience is a clinical-stage biopharmaceutical company that develops precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO, is a form of sirolimus bound to albumin. The company is evaluating FYARRO in cancers with known mTOR pathway activation and is headquartered in Pacific Palisades, California.